903512-50-5
903512-50-5 structure
- Name: Lucatumumab
- Chemical Name: Lucatumumab
- CAS Number: 903512-50-5
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2022-10-11 19:32:12
- Modify Date: 2024-01-12 07:59:01
-
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2].
| Name | Lucatumumab |
|---|
| Description | Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CD40[1] |
| In Vitro | Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%[1]. Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells[1]. Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells[1]. Cell Viability Assay[1] Cell Line: B-cell chronic lymphocytic leukemia (B-CLL) Concentration: 0.001 to 10 μg/mL Incubation Time: 72 hours; 37 ℃ Result: Inhibited B-CLL growth with an ED50 of 14 pM and a average maximal lysis of B-CLL cells of 49%. |
| References |
| No Any Chemical & Physical Properties |